Legend Biotech (传奇生物) Pre-IPO: A Good Deal for the Promising CAR-T
Legend Biotech, a subsidiary of Hong Kong-listed GenScript, started book building to raise up to USD 368 million via an IPO. The company has a...
443 Views
Legend Biotech (传奇生物) Pre-IPO: Superior Efficacy Vs Bluebird/BMS Candidate
Legend Biotech, a subsidiary of Hong Kong-listed GenScript, is planning to raise up to USD 300 million via an IPO. The company has a strong focus...
459 Views
Legend Biotech IPO Initiation: Choosing Therapies À La CAR-T
Legend Biotech (BLG US) is one of the leading companies in developing CAR-T cell therapies in China, having received clearance for the first CAR-T...
316 Views
S&P 500 and S&P 600 Testing Resistance...Still
The S&P 500 is beginning to come off of short-term overbought extremes, consolidating near the confluence of key overhead resistance and the...
295 Views
We Are Buying This Large Cap Biotechnology Company After Trump's Election Win
We have a Buy rating with price target of $173 (DCF method)=44% upside. The stock also appears to have upside using relative valuation measures...
669 Views